Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2019

09.08.2019 | Clinical trial

Phase II randomized controlled trial of hypnosis versus progressive muscle relaxation for body image after breast or gynecologic cancer

verfasst von: Debra L. Barton, Trevor M. Brooks, Alison Cieslak, Gary R. Elkins, Patricia M. Clark, Mohamad Baydoun, Asa B. Smith, Catherine H. Van Poznak

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Sexual dysfunction, fueled by body image stress, is prevalent in women with a history of breast or gynecologic cancer. Preliminary data support that mind–body connections may improve sexual health outcomes through improving body image.

Objective

This randomized controlled trial compared hypnosis to progressive muscle relaxation (PMR). The primary outcome was body image at week 6 as measured by the Impact of Treatment Scale for women who have or have had breast or gynecologic cancer.

Interventions/Methods

Consented participants were randomized 2:1 to hypnosis or PMR. Both arms consisted of three face-to-face sessions delivered by a trained therapist. Sessions were every 2 weeks for 6 weeks; participants practiced at home between sessions using an audio recording.

Results

Eighty-seven women were randomized, 59 to hypnosis and 28 to PMR. Both groups reported significant improvements on body image over time (within group effect size Cohen’s d = 0.49–0.75) with no significant difference between groups (p = 0.15). Secondary outcomes were not significantly different between groups. The hypnosis group improved more in sexual satisfaction and sexual interest while the PMR group improved more in positive affect.

Conclusions

Interventions facilitating mind–body connections such as hypnosis and PMR may help to improve body image. This study suggests that stress relieving strategies of hypnosis and PMR may contribute to providing a re-connection to one’s body, improved positive affect, and overall better sexual health.
Literatur
10.
Zurück zum Zitat Crasilneck HB, Hall JA (1985) Clinical hypnosis principles and aplications, 2nd edn. Grune and Stratton, New York Crasilneck HB, Hall JA (1985) Clinical hypnosis principles and aplications, 2nd edn. Grune and Stratton, New York
12.
Zurück zum Zitat Hypnosis ASoC (1990) Handbook of hypnotic suggestions and metaphors. WW Norton & Company, New York Hypnosis ASoC (1990) Handbook of hypnotic suggestions and metaphors. WW Norton & Company, New York
15.
Zurück zum Zitat Andersen BL, Cyranowski JM (1994) Women’s sexual self-schema. J Pers Soc Psychol 67(6):1079–1100CrossRef Andersen BL, Cyranowski JM (1994) Women’s sexual self-schema. J Pers Soc Psychol 67(6):1079–1100CrossRef
16.
Zurück zum Zitat Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54(6):1063–1070CrossRef Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54(6):1063–1070CrossRef
18.
Zurück zum Zitat Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C (2002) Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc 77(5):479–487CrossRefPubMed Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C (2002) Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc 77(5):479–487CrossRefPubMed
21.
Zurück zum Zitat Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, Diefenbach MA, DuHamel K, Florendo J, Ganz PA, Goldfarb S, Hallmeyer S, Kushner DM, Rowland JH (2018) Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol 36(5):492–511. https://doi.org/10.1200/jco.2017.75.8995 CrossRefPubMed Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, Diefenbach MA, DuHamel K, Florendo J, Ganz PA, Goldfarb S, Hallmeyer S, Kushner DM, Rowland JH (2018) Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol 36(5):492–511. https://​doi.​org/​10.​1200/​jco.​2017.​75.​8995 CrossRefPubMed
Metadaten
Titel
Phase II randomized controlled trial of hypnosis versus progressive muscle relaxation for body image after breast or gynecologic cancer
verfasst von
Debra L. Barton
Trevor M. Brooks
Alison Cieslak
Gary R. Elkins
Patricia M. Clark
Mohamad Baydoun
Asa B. Smith
Catherine H. Van Poznak
Publikationsdatum
09.08.2019
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05395-6

Weitere Artikel der Ausgabe 2/2019

Breast Cancer Research and Treatment 2/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.